Roche Holdings AG Basel ADR (OTC: RHHBY) said Monday that it has signed a licensing agreement with Sarepta Therapeutics Inc (NASDAQ: SRPT) to acquire the commercial rights to the latter s investigational gene therapy asset SRP-9001 outside of the U.S. The asset is being evaluated in. Read More.